Investigation of the Efficacy of Intra-articular Prolotherapy on the Primary Osteoarthritis of Knee: Patients’ Level of Pain and Knee Joint’s Range of Motion

Investigation of the Efficacy of Intra-articular Prolotherapy With Erythropoietin and Dextrose and Intra-articular Pulsed Radiofrequency on the Primary Osteoarthritis of Knee: Patients’ Level of Pain and Knee Joint’s Range of Motion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013092210336N4

Enrollment

Registered

2013-10-27

Start date

2013-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis.

Interventions

Intervention 1: Prolotherapy with dextrose. Intervention 2: Prolotherapy with erythropoetine. Intervention 3: Intraarticular radiofrequency.

Treatment - Drugs

Prolotherapy with dextrose

Prolotherapy with erythropoetine

Intraarticular radiofrequency

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were: osteoarthritis according to the American College of Rheumatology’s (formerly, American Rheumatology Association) criteria; age 40-70 years old; clinical class I-III; radiology stage 1-3 based on Kellgren-Lawrence criteria. The exclusion criteria were: drugs or alcohol addiction; hemophilia; rheumatoid arthritis or other rheumatologic disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Knee pain amount. Timepoint: Weeks 2, 4 and 12. Method of measurement: Visual analogue scale(VAS).;Range of motion of knee. Timepoint: Weeks 2, 4 and 12. Method of measurement: Goniometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPoupak Rahimzadeh

Iran University of Medical Sciences

p-rahimzadeh@tums.ac.ir+98 912 106 4483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026